Time course of adverse events most commonly associated with topiramate for migraine prevention

European Journal of Neurology

Volumn 14, Issue 8, 2007, Pages 900-906

  Lainez M J A ^a   Freitag, F G ^b   Pfeil, J ^c   Ascher, S ^d   Olson, W H ^d   Schwalen, S ^e  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b DIAMOND HEADACHE CLINIC   (United States)

^c Estimate Medical Statistics BV   (Netherlands)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e JANSSEN CILAG GMBH   (Germany)

Author keywords

Adverse events; Safety; Tolerability; Topiramate

Indexed keywords

PLACEBO; PROPRANOLOL; TOPIRAMATE;

ADULT; AGED; ANOREXIA; ANXIETY; ARTICLE; CHILD; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADULT; ANOREXIA; ANTICONVULSANTS; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NAUSEA; PARESTHESIA; PATIENT COMPLIANCE; PLACEBOS; TIME; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 34547132775     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2007.01869.x     Document Type: Article

References (21)

1. Dahlof CG, Dimenas E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995 15 : 31 36.
2. MacGregor EA, Brandes J, Eikermann A, Giammarco R. Impact of migraine on patients and their families: the migraine and zolmitriptan evaluation (MAZE) survey - phase III. Current Medical Research and Opinion 2004 20 : 1143 1150.
3. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression. Neurology 2000 55 : 629 635.
4. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American migraine study II. Headache 2001 41 : 646 657.
5. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia 2003 23 : 441 450.
6. Terwindt GM, Ferrari MD, Tijhuis M, Groenen SM, Picavet HS, Launer LJ. The impact of migraine on quality of life in the general population: the GEM study. Neurology 2000 55 : 624 629.
7. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002 8 : 885 894.
8. Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO's classification of functioning, disability and health (ICF). Journal of Headache and Pain 2005 6 : 429 440.
9. Loder E, Silberstein S, Diamond S, Reed ML, Bigal M, Lipton R. Candidates for preventive migraine therapy in a community sample: results from the American migraine prevalence and prevention (AMPP) study. Presented at the 58th Annual Meeting of the American Academy of Neurology; April 1-8, 2006; San Diego, California. Abstract #PO4.091.
10. Lipton R, Bigal M, Stewart WF, Freitag FG, Reed ML. Barriers to migraine preventive medication use in a community sample: results from the American Migraine Prevalence and Prevention (AMPP) study. Presented at the 58th Annual Meeting of the American Academy of Neurology; April 1-8, 2006; San Diego, California. Abstract #S17.002.
11. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 2003 43 : 36 43.
12. Massiou H. Migraine medication attributes are important for patient compliance. Drugs of Today (Barcelona), 2003 39 (Suppl D 25 29.
13. Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurologica Scandinavica Supplement 2005 181 : 30 35.
14. Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia 2000 41 (Suppl. 1 S61 S65.
15. Majkowski J, Neto W, Wapenaar R, Van Oene J. Time course of adverse events in patients with localization-related epilepsy receiving topiramate added to carbamazepine. Epilepsia 2005 46 : 648 653.
16. Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Archives of Neurology 2004 61 : 490 495.
17. Brandes JL, Saper JR, Diamond M, MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. Journal of the American Medical Association 2004 291 : 965 973.
18. Diener HC, Tfelt-Hansen P, Dahlof C, MIGR-003 Study Group. Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control. Journal of Neurology 2004 251 : 943 950.
19. Bussone G, Diener HC, Pfeil J, Schwalen S. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled. International Journal of Clinical Practice 2005 59 : 961 968.
20. Lin DY, Wei LJ, Yang I, Ying Z. Semiparametric regression for the mean and rate functions of recurrent events. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 2000 62 : 711 730.
21. Freitag F, Lainez MJA, Neto W, Shi Y. Comparing the incidence of adverse events in the titration and maintenance phases of placebo-controlled trials of topiramate for migraine prevention. Presented at the 57th Annual Meeting of the American Academy of Neurology; April 9-16, 2005; Miami Beach, Florida. Abstract #P05.159.